AI Signal & Stock Analysis · Weak ↓
As of Aug 14 2026, 1:04 PM, AkshayaAI's signal for NBIX is Weak ↓; the stock is at $152.37 (+1.03% today); neutral (RSI 35); technical trend is down-trend; news sentiment is positive.
Data as of Aug 14 2026, 1:04 PM. Informational analytics only — not investment advice.
| AI signal (Strength) | Weak ↓ |
|---|---|
| Price | $152.37 |
| Change today | +1.03% |
| RSI (14) | 34.57 |
| Relative volume | 0.82 |
| Composite (RMTPGV) score | 🔒 members |
| Market cap | $15.5B |
| Forward P/E | 15.71 |
| 52-week high | -18.2% away |
| 52-week low | +24.6% above |
| Technical trend | Down-trend (since 2024-01-26) |
| News sentiment | Positive |
| Sector | Healthcare-Pharma |
| Next earnings | 7/30/2026 4:30:00 PM |
As of Aug 14 2026, 1:04 PM, AkshayaAI assigns NBIX (Neurocrine Biosciences Inc) a Weak signal. The composite (RMTPGV) score and full factor breakdown are available to signed-in members.
NBIX's RSI is neutral (RSI 35). A reading above 70 is typically considered overbought and below 30 oversold.
NBIX is trading about 18% below its 52-week high and 25% above its 52-week low as of Aug 14 2026, 1:04 PM.
NBIX's next earnings date is 7/30/2026 4:30:00 PM.
NBIX is classified under Healthcare-Pharma in AkshayaAI's taxonomy.
AkshayaAI provides AI-generated, informational stock analytics for US and India markets. This is not personalized investment advice. Figures are as of Aug 14 2026, 1:04 PM and may not reflect real-time prices. Always do your own research.
Instant, data-backed answers — free to try.